Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 16, 2020 6:25am EDT

Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

Aug 31, 2020 4:01pm EDT

Lexaria Bioscience Announces R&D Agreement With British American Tobacco

Aug 20, 2020 7:17am EDT

Lexaria Bioscience to Present at the LD 500 Virtual Conference

Jul 28, 2020 6:30am EDT

Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Jul 21, 2020 6:15am EDT

Lexaria BioScience Files Application with Senior U.S. Stock Exchange for Uplisting

Jul 16, 2020 6:15am EDT

Altria and Lexaria Conclude Phase I Research and Development Program

Jun 29, 2020 4:15pm EDT

Lexaria Bioscience Engages Investor Relations and Capital Markets Advisory Firm for its Shareholder Communications Program

Jun 24, 2020 6:15am EDT

Lexaria Announces 2020 Annual and Special Meeting Results

Jun 18, 2020 6:30am EDT

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

Jun 01, 2020 4:35pm EDT

Lexaria Bioscience Engages PCG Advisory, Inc, to Provide Investor Relations Services

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2022 All rights reserved.

Back to the top